Coronavirus disease

RAK Hospital in UAE unveils Free Online COVID-19 Rehabilitation Program for COVID patients across the globe

Retrieved on:

Tuesday, March 16, 2021

Emirates of the United Arab Emirates, Respiratory diseases, Health, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, RAK Hospital, RAK, Ras Al Khaimah, Severe acute respiratory syndrome

Emerging evidence indicates that a majority of people who require hospitalization for COVID- 19 experience sequelae such as fatigue and shortness of breath in the months following their hospital discharge.

Key Points:

Emerging evidence indicates that a majority of people who require hospitalization for COVID- 19 experience sequelae such as fatigue and shortness of breath in the months following their hospital discharge.
Studies have also shown that the COVID causing SARS-COV-2 virus is likely to linger in the body, for many months.
Ours is the only initiative providing an integrated and holistic approach to COVID recovery and rehabilitation, offered complimentary to all recovering patients", commented Dr Raza Siddiqui, Executive Director, RAK Hospital, a multi-disciplinary hospital based in Ras Al Khaimah, UAE.
"RAK Hospital had introduced its physical post COVID recovery rehabilitation program last year.

Cytocom Receives FDA Clearance of IND for Phase 2 Clinical Trial of CYTO-205 as Treatment for COVID-19

Retrieved on:

Tuesday, March 16, 2021

Medical specialties, Health, Medicine, Acute respiratory distress syndrome, Intensive care medicine, Respiratory physiology, Coronavirus disease, Immune system, Respiratory distress syndrome, Ards

CYTO-205is designed to modulate immune system function, decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.

Key Points:

CYTO-205is designed to modulate immune system function, decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.
During Stage 3, or the hyperinflammation phase of COVID-19, patients can develop acute respiratory distress syndrome (ARDS), sepsis, and kidney and other organ failures.
Specifically, Cytocom has four programs in late-stage clinical development for Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer.
The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients

Retrieved on:

Tuesday, March 16, 2021

Medicine, Branches of biology, Clinical medicine, Occupational safety and health, Biomarkers, Biotechnology, Chemical pathology, Coronavirus disease

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

Key Points:

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy.
This study of emricasan in symptomatic COVID-19 patients marks a significant milestone for Histogen and our partner Amerimmune as we enter the fight against this unprecedented pandemic, said Richard W. Pascoe, President and Chief Executive Officer of Histogen.
Our first treatment in this clinical trial is an important step toward potentially bringing new and promising treatments to patients with mild COVID-19.
Amerimmune will support the Phase 1 study of emricasan in mild COVID-19 patients by carefully evaluating biomarkers of antibody, T cell and caspase related immunity in patients receiving the pan-caspase inhibitor.

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

Retrieved on:

Tuesday, March 16, 2021

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.

Key Points:

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.
Results of the screening also indicate that identified antibodies retain the ability to bind to emerging SARS-CoV-2 variants including U.K. (B.1.1.7 lineage), S. African (B.1.351 lineage) and Brazilian (P.1 lineage) strains.
Researchers studying SARS-CoV-2, the virus that causes COVID-19, have indicated that global variants are more transmissible than the original strain.
The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date.

Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus

Retrieved on:

Monday, March 15, 2021

Zoonoses, Health, Branches of biology, Pandemics, Medical tests, Genetic mapping, Genomics, Coronavirus disease, Virus, Severe acute respiratory syndrome coronavirus, Genome

Under the agreement, Fulgent Genetics will sequence the genomes of random samples that have tested positive for SARS-CoV-2, the virus that causes COVID-19.

Key Points:

Under the agreement, Fulgent Genetics will sequence the genomes of random samples that have tested positive for SARS-CoV-2, the virus that causes COVID-19.
Fulgent will leverage its NGS platform and provide sequencing data to the CDC as part of their initiative to conduct a large-scale genomic survey of the virus using random samples from across the United States.
Ultimately, the CDC believes this large-scale genomic survey of the virus can provide important baseline information for national and state-level virus surveillance, help define important changes in transmission, help to identify unusual or emerging variants, and ultimately improve the public health response to the virus.
We are pleased to be able to leverage our NGS capabilities to aid the CDC in the study of SARS-CoV-2, said Dr. Harry Gao, Chief Scientific Officer at Fulgent Genetics.

Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells

Retrieved on:

Monday, March 15, 2021

Medical specialties, Coronaviridae, Sarbecovirus, Medicine, Immunology, Cytokine storm, Endocrine system, Coronavirus disease, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Sherry Chou, COVID-19 drug repurposing research

Our COVID-19 research program has yielded some truly extraordinary results, demonstrating apabetalones ability to prevent SARS-CoV-2 infection of human lung cells, said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development at Resverlogix.

Key Points:

Our COVID-19 research program has yielded some truly extraordinary results, demonstrating apabetalones ability to prevent SARS-CoV-2 infection of human lung cells, said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development at Resverlogix.
We are grateful to work with world-class scientific leaders to characterize apabetalone as a therapeutic for COVID-19 infection for the future benefit of patients.
Resverlogix has announced plans for an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19.
First, apabetalone treatment prevents SARS-CoV-2 from infecting human cells (as highlighted in this work), and second it reduces the inflammation and cytokine storm response which can result in organ damage and long-term negative impacts.

Blueair Introduces DustMagnet™ Air Purifiers with a Stylish Design for a Life with Less Cleaning

Retrieved on:

Monday, March 15, 2021

Family, Retail, Consumer electronics, Consumer, Technology, Home Goods, Sarbecovirus, Respiratory diseases, Health, Zoonoses, Occupational safety and health, Air purifier, Filters, Coronavirus disease, Severe acute respiratory syndrome, Coronavir, HEPA

View the full release here: https://www.businesswire.com/news/home/20210315005088/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20210315005088/en/
Consumers shouldnt have to compromise on design when it comes to having clean air inside their home, said Jonas Holst, Chief Product Officer at Blueair.
In addition to its stylish design to match any interior, DustMagnet is designed for a life with less cleaning, offering high-performance air filtration.
More Clean Air, Less Energy and Noise: Equipped with Blueairs HEPASilent technology, DustMagnet delivers more2 clean air using less energy3 and emitting less noise.
Blueair purifiers are not tested against Coronavirus & Blueair does not claim to capture, remove, or kill SARS-CoV-2 (COVID-19).

ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time

Retrieved on:

Monday, March 15, 2021

COVID-19 testing, Medicine, Coronavirus disease, Dietary supplement, Health sciences, Health, Medical tests

The Companys laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories.

Key Points:

The Companys laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories.
Critical to Covid testing, results are typically provided in under 24 hours.
ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others.
ProPhase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements brand.

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

Retrieved on:

Monday, March 15, 2021

Medical specialties, Immunology, Health, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, Cytokine

This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19.

Key Points:

This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19.
Treatment with Tempol reduces the overall inflammatory responses and appears to start repairing damaged lungs.
The results demonstrated that incubation of Tempol significantly suppresses multiple inflammatory cytokines from cells taken from COVID-19 patients.
The new results demonstrating decreased lung inflammation in hamsters challenged and treated with Tempol are consistent with the design of the recent FDA allowed IND and protocol to study Tempol in early COVID-19 infection.

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

Retrieved on:

Monday, March 15, 2021

Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with health care providers to reduce symptoms.

Key Points:

Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with health care providers to reduce symptoms.
At-home steps to reduce COVID-19 symptoms:
Confusion and Brain Fog: Although brain fog is not a true medical condition, it is a common symptom for many COVID-19 patients.
A healthy diet is recommended and encouraged, and when ready, physical activity and memory exercises can help jumpstart brain alertness.
Monitor your Health Post-Infection: Unfortunately, long-haul COVID-19 symptoms are very common, even for people who experienced a mild case initially.